Posted on 12 October 2020
Longevity briefs provides a short summary of a novel research, medicine, or technology that caught the attention of our researchers in Oxford, due to its potential to improve our health, wellbeing, and longevity.
Why is this research important: Alzheimers is the most common form of dementia, a neurological condition which sees the degradation of cognitive ability to a senile state, eventually resulting in death. In the UK alone there are currently 850,000 people living with some form of dementia, this is predicted to rise to over 2 million people by 2050.
(You can check out a talk by Prof. Chas Bountra, vice chancellor of the University of Oxford, highlighting our current, and future, battle with dementia on the Gowing Life youtube page.)
What did the researchers do: In a bid to uncover more about the genesis of Alzheimer’s disease, a team led by Dr. Shelley Berger of the University of Pennsylvania, USA, analysed post-mortem human brains of Alzheimer’s victims. The researchers used RNA sequencing, proteomics and transcriptomics to try to identify the molecular causes of the condition.
Key takeaway(s) from this research: The analysis revealed that epigenetic modifications H3K27ac and H3K9ac were significantly upregulated in Alzheimer’s disease tissue samples. Epigenetic modifications are changes to the biochemical mechanisms that control the regulation of gene expression, otherwise known as the epigenome.
The study also showed that increasing these epigenetic modifications in the genome of flies leads to an exacerbated Alzheimer’s phenotype.
The investigation indicates that H3K27ac and H3K9ac are important epigenetic drivers of Alzheimer’s disease which present potential targets for therapeutics.
Scientifically Developed Blended Vitamins, and Exclusive Supplements For Health, and Longevity